dm+d

Unassigned

New Medicines

Muscle invasive bladder cancer - with gemcitabine intravesical delivery system

Information

New molecular entity
Janssen
Johnson & Johnson

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

A monoclonal antibody targeting programmed cell death 1 receptor. Cetrelimab binds to PD-1, and inhibits the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signalling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumour cells.
Bladder cancer is the 4th most common cancer in men and the 11th most common in women. The overall incidence in the UK is 11.4 per 100,000 population. At diagnosis, only about 5% of patients have metastatic disease, usually to lymph nodes, lung, liver, bone and central nervous system. Around 30% have involvement of the muscle layer. Around 70% have superficial disease, of which 10% is CIS [1].
Muscle invasive bladder cancer - with gemcitabine intravesical delivery system
Intravenous